

## Results of NeoDynamics' PULSE study presented at the 42nd Annual Congress of the German Society of Senology, Munich

**Last week, NeoDynamics had the opportunity to present the results of its PULSE study at the Annual Congress of the German Society of Senology in Munich with more than 2,000 participants.**

One of the purposes of the congress, which took place on July 6-8, 2023, in Munich, is to stimulate the exchange of experience between clinicians from different medical disciplines and service providers in the health care system. German Key Opinion Leaders presented results of the PULSE study based on the final data set at the congress.

NeoDynamics' PULSE study is a German prospective multicenter study (ClinicalTrials.gov ID: NCT03975855) designed to document the performance of the NeoNavia biopsy device in the axillary lymph nodes on 138 enrolled patients. Professor Marc Thill, from Agaplesion Markus Krankenhaus, Frankfurt, has been principal investigator, and presented a poster on the study results. Additionally, Dr. Stefan Paepke, from TU Munich r.d. Isar presented the PULSE data during a scientific session on "Minimally-invasive Diagnostics and Therapy" on the last day.

The study has demonstrated that pneumatic pulses promoted high needle control and stabilization of target lesions during insertion of the needle and that it was possible to obtain multiple samples with a single insertion.

"We want to and need to perform fewer surgeries and more minimally-invasive procedures in breast cancer patients. That concerns the tumor in the breast and the associated axillary lymph nodes. The data once again shows that NeoNavia is a valuable tool supporting this development," says Dr. Stefan Paepke.

**For further information, please contact:**

Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail [anna.eriksrud@neodynamics.com](mailto:anna.eriksrud@neodynamics.com)

Aaron Wong, CFO NeoDynamics AB, phone +46790 101 714 or e-mail [aaron.wong@neodynamics.com](mailto:aaron.wong@neodynamics.com)

**About NeoNavia**

NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumor whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.

## **About NeoDynamics**

NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company's first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and launches in USA during 2023. NeoDynamic's shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company's Certified Adviser is Redeye AB.

## **About Karolinska Institute**

The Karolinska Institute is consistently ranked amongst the world's best medical schools, ranking 6th worldwide for medicine in 2021. The Nobel Assembly at the Karolinska Institute awards the Nobel Prize in Physiology or Medicine.

## **Attachments**

[Results of NeoDynamics' PULSE study presented at the 42nd Annual Congress of the German Society of Senology, Munich](#)